Notice 29 Jul 2025 regulatory compliance, healthcare, business operations, fda, export requirements

📦FDA Review of Export Notification and Recordkeeping Requirements

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

Learn More
Notice 29 Jul 2025 compliance, healthcare, regulation, fda, public health, animal health, xenotransplantation

🧬FDA Information Collection on Infectious Disease in Xenotransplantation

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

Learn More
Notice 29 Jul 2025 compliance, healthcare, regulations, fda, medical devices

📋FDA Medical Device Reporting Requirements and Compliance Overview

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

Learn More
Notice 29 Jul 2025 regulatory compliance, fda, drug development, tropical diseases, priority review vouchers

💊FDA Notice on Tropical Disease Priority Review Vouchers Collection

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

Learn More
Notice 29 Jul 2025 compliance, regulation, fda, user fees, data collection, tobacco

🏭FDA Notice on Tobacco Products User Fees and Data Submission Requirements

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

Learn More
Notice 29 Jul 2025 compliance, fda, import regulations, food safety, food importers, supplier verification

📦FDA Notice on Foreign Supplier Verification Program for Food Importers

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

Learn More
Notice 29 Jul 2025 compliance, regulations, fda, food industry, dietary supplements

🥗FDA Notification Procedures for Dietary Supplements

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

Learn More
Notice 29 Jul 2025 regulatory compliance, healthcare, fda, veterinary, animal drugs, compounding

🐾FDA Notice on Compounding Animal Drugs from Bulk Substances

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

Learn More
Notice 29 Jul 2025 compliance, regulations, fda, health, food, medical devices, drug

📄FDA Information Collection Approvals and Business Implications

The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

Learn More
Notice 29 Jul 2025 regulatory compliance, healthcare, pharmaceuticals, fda, emergency use authorization, covid-19

💊FDA Revokes Emergency Use Authorizations for COVID-19 Drugs

The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorizations (EUAs) (the Authorizations) issued to Regeneron Pharmaceuticals, Inc. (Regeneron) for REGEN-COV (casirivimab and imdevimab administered together), to GlaxoSmithKline LLC (GSK) for sotrovimab, to Eli Lilly and Company (Lilly) for bebtelovimab, and to AstraZeneca Pharmaceuticals LP (AstraZeneca) for EVUSHELD (tixagevimab co-packaged with cilgavimab). FDA revoked these Authorizations on December 13, 2024, under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The revocations, including an explanation of the reasons for the revocations, are reprinted in this document.

Learn More